TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8638526

Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrates alone or in combination with hydralazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent dosing of nitrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escalating dose regimen of nitrates with hydralazine
Number of subjects: 0
Study: 1503483

Group type: EXPERIMENTAL
Intervention: Modified FAM (5-FU + ADR + MMC) therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: 5-FU mono-therapy
Number of subjects: 71
Study: 6476623

Group type: COMPARATOR
Intervention: Intermittent rectal diazepam (0.5 mg/kg every 8 hours during fever)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral phenobarbital (BID)
Number of subjects: 100
Study: 29533112

Group type: EXPERIMENTAL
Intervention: Focused ultrasound treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-treated contralateral flanks)
Number of subjects: 0
Study: 29528419

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) of the resection cavity and single- or multisession SRT of all unresected brain metastases (up to 10 lesions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 50
Study: 26854906

Group type: EXPERIMENTAL
Intervention: MVA85A-IMX313 (low dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MVA85A-IMX313 (standard dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MVA85A
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MVA85A-IMX313
Number of subjects: 30
Study: 24401829

Group type: EXPERIMENTAL
Intervention: Real-time feedback of movement-associated cortical activity (beta band 16-28 Hz) using a brain-computer interface (BCI) system during mental practice training.
Number of subjects: 10

Group type: COMPARATOR
Intervention: No EEG cortical feedback during mental practice training.
Number of subjects: 10
Study: 23147404

Group type: EXPERIMENTAL
Intervention: Endovascular closure of the PFO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-PFO-related ischemic stroke
Number of subjects: 0
Study: 19764180

Group type: EXPERIMENTAL
Intervention: Legislative effort to prevent falls from height in construction
Number of subjects: 0
Study: 17177960

Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg transcutaneous patch)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16000961

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (3 x 10(6) IU/m2/d) administered subcutaneously for 42 days
Number of subjects: 93
Study: 12387527

Group type: EXPERIMENTAL
Intervention: N 25 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: N 50 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9814633

Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale (GOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disability Rating Scale (DRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between DRS and GOS
Number of subjects: 0
Study: 8137624

Group type: EXPERIMENTAL
Intervention: GES/EE (gestodene 75 mcg/ethinyl oestradiol 30 mcg)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: DES/EE (desogestrel 150 mcg/ethinyl oestradiol 20 mcg)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: GES/EE
Number of subjects: 1006

Group type: COMPARATOR
Intervention: DES/EE
Number of subjects: 1006
Study: 2536537

Group type: EXPERIMENTAL
Intervention: Topical application of calcitriol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of active forms of vitamin D3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal serum level of 1 alpha,25‐dihydroxyvitamin D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other calcium‐related parameters
Number of subjects: 0
Study: 30279219

Group type: EXPERIMENTAL
Intervention: '11+ Kids' injury prevention programme (INT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular training regime (CON)
Number of subjects: 0
Study: 29168959

Group type: EXPERIMENTAL
Intervention: Training program on neonatal care (3 sessions)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 116
Study: 25330801

Group type: EXPERIMENTAL
Intervention: CHIEF pathway
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: At-risk alleles
Number of subjects: 1555
Study: 22995539

Group type: EXPERIMENTAL
Intervention: E(2)V/DNG oral contraceptive
Number of subjects: 100
Study: 21774987

Group type: EXPERIMENTAL
Intervention: 12-month socioculturally adapted collaborative care (psychotherapy and/or antidepressants, telephone symptom monitoring/relapse prevention)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: 12-month socioculturally adapted collaborative care
Number of subjects: 387
Study: 19631861

Group type: EXPERIMENTAL
Intervention: PTFE ACUSEAL patch
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hemashield Finesse patch
Number of subjects: 200

Group type: COMPARATOR
Intervention: PTFE ACUSEAL patch and Hemashield Finesse patch
Number of subjects: 200
Study: 16858558

Group type: EXPERIMENTAL
Intervention: Outside-in technique (group A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Inside-out technique (group B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: All-inside technique (group C)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Operation time for group A
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Operation time for group B
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Operation time for group C
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Complications among groups
Number of subjects: 57
Study: 15213476

Group type: EXPERIMENTAL
Intervention: Structured nursing intervention (12 consecutive weekly meetings)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Routine rehabilitation program (control group)
Number of subjects: 155
Study: 12237729

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-fibrinolytics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (intraoperative use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DDAVP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous predonation
Number of subjects: 0
Study: 9641732

Group type: EXPERIMENTAL
Intervention: Once daily growth hormone injection (group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Twice daily growth hormone injections (group B)
Number of subjects: 49
Study: 7853436

Group type: EXPERIMENTAL
Intervention: Mebendazole treatment in Group A
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo in Group B
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Mebendazole treatment in Group B
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Mebendazole treatment in Group C
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo in Group D
Number of subjects: 49
Study: 2910422

Group type: EXPERIMENTAL
Intervention: Infusor (Baxter Healthcare Corporation) for outpatient CVI chemotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard inpatient CVI chemotherapy delivery device (standard pump)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Infusor (Baxter Healthcare Corporation) for inpatient CVI chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Outpatient CVI chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CVI chemotherapy (both methods)
Number of subjects: 22
Study: 1130305

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (small daily dose)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Food fortification with folic acid
Number of subjects: 431
Study: 26014293

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC)
Number of subjects: 436

Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 436
Study: 22959620

Group type: EXPERIMENTAL
Intervention: Synbiotic (6 g, two daily doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 100
Study: 21292332

Group type: EXPERIMENTAL
Intervention: Steroid antibiotic pack (Betnovate-N: betnovate sodium phosphate 0.1% and neomycin sulphate 0.5%)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 10% ichthammol glycerine pack
Number of subjects: 65
Study: 19479252

Group type: EXPERIMENTAL
Intervention: GIPET-enhanced oral acyline 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GIPET-enhanced oral acyline 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GIPET-enhanced oral acyline 40 mg
Number of subjects: 8
Study: 17286537

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 352
Study: 15179240

Group type: EXPERIMENTAL
Intervention: Educational intervention on seat belt use during pregnancy
Number of subjects: 735
Study: 11297832

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 9144824

Group type: EXPERIMENTAL
Intervention: Outreach case management team
Number of subjects: 289

Group type: COMPARATOR
Intervention: Standard aftercare (Control)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Case management team
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 289
Study: 8190577

Group type: EXPERIMENTAL
Intervention: rHuEpo (Eprex, 600 U/kg per week)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30460996

Group type: EXPERIMENTAL
Intervention: Brand bupropion XL 300 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Generic bupropion XL 300 mg
Number of subjects: 70
Study: 26356398

Group type: EXPERIMENTAL
Intervention: Baclofen (50 mg/day) for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23518240

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 160
Study: 21547598

Group type: EXPERIMENTAL
Intervention: BMMC + CRTinact (BMMC therapy only)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BMMC + CRTact (BMMC therapy + CRT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BMMC + CRTact and BMMC + CRTinact
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BMMC + CRTinact
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BMMC + CRTact
Number of subjects: 26
Study: 18695661

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow cell transplantation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (patients who did not enroll in the study)
Number of subjects: 10
Study: 16161123

Group type: EXPERIMENTAL
Intervention: Lyophilized bone chips supplemented with platelet gel (PG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lyophilized bone chips without gel
Number of subjects: 10
Study: 12662013

Group type: EXPERIMENTAL
Intervention: Ramp incremental cycle ergometry
Number of subjects: 120
Study: 11100985

Group type: EXPERIMENTAL
Intervention: alpha fetoprotein (AFP) and ultrasonography screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: surgical resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: intra-arterial chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: systemic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: multimodality combination and sequential treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: conformal radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tamoxifen
Number of subjects: 0
Study: 8960716

Group type: EXPERIMENTAL
Intervention: Physostigmine (18, 24, or 30 mg daily)
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 1111
Study: 1404122

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 4052935

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Doxorubicin plus cisplatin
Number of subjects: 37
Study: 30777311

Group type: EXPERIMENTAL
Intervention: Guided waves (500‐kHz bi‐directional axial transmission)
Number of subjects: 15
Study: 29432907

Group type: EXPERIMENTAL
Intervention: Enhanced standard of care and 4 text messages a week through 6 months (n=108 completing)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Enhanced standard of care materials at well-child visits through 6 months (n=99 completing)
Number of subjects: 231
Study: 27356240

Group type: EXPERIMENTAL
Intervention: Ω‐3 + OLE
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo milk
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 25194850

Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program delivered by community healthcare workers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 23617982

Group type: EXPERIMENTAL
Intervention: Government-mandated nutrition information
Number of subjects: 687

Group type: COMPARATOR
Intervention: Industry labelling (voluntary calorie symbols)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Coke® bottle with calorie amounts per serving
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Coke® bottle with calorie amounts per container
Number of subjects: 687
Study: 19959493

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH; 5000 IU twice daily)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Treatment modalities (both enoxaparin and UFH)
Number of subjects: 341
Study: 17669110

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily (ALL-500 group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Levofloxacin 1000 mg twice daily (ALL-1000 group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Post-treatment value of (13)C-urea breath test <= 15 in ALL-500 group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Post-treatment value of (13)C-urea breath test > 15 in ALL-500 group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Post-treatment value of (13)C-urea breath test <= 15 in ALL-1000 group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Post-treatment value of (13)C-urea breath test > 15 in ALL-1000 group
Number of subjects: 124
Study: 16478369

Group type: EXPERIMENTAL
Intervention: Concurrent feedback group (real-time EMG waveform displays)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Terminal feedback group (static terminal EMG waveform displays)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control sites (orofacial, no-feedback)
Number of subjects: 22
Study: 11999591

Group type: EXPERIMENTAL
Intervention: Axillary block with limb placed on thorax
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Axillary block with limb placed in abduction
Number of subjects: 81

Group type: COMPARATOR
Intervention: Transient visualization of the limb position
Number of subjects: 81
Study: 15511994

Group type: EXPERIMENTAL
Intervention: Blunt-tipped needles
Number of subjects: 204

Group type: COMPARATOR
Intervention: Sharp-tipped needles
Number of subjects: 204
Study: 7534450

Group type: EXPERIMENTAL
Intervention: Hebrew version of the MAP administered to Israeli children
Number of subjects: 60

Group type: COMPARATOR
Intervention: U.S. norms on the MAP
Number of subjects: 60
Study: 2231376

Group type: EXPERIMENTAL
Intervention: Methylcellulose
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sodium hyaluronate
Number of subjects: 70
Study: 20727

Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 to 0.6 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (equipotent doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone (control)
Number of subjects: 0
Study: 29699895

Group type: EXPERIMENTAL
Intervention: Cognitive training of auditory processing systems (N = 47)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Computer games control condition (N = 43)
Number of subjects: 90
Study: 29121183

Group type: EXPERIMENTAL
Intervention: Primary EN‐DCR within 2 weeks of presentation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Percutaneous drainage of lacrimal sac abscess followed by EN‐DCR after the acute episode subsided (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 25861099

Group type: EXPERIMENTAL
Intervention: 3-day empathy simulation intervention (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study: 24050859

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 4989
Study: 21297074

Group type: EXPERIMENTAL
Intervention: Tifacogin 0.025 mg/kg/h
Number of subjects: 2138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2138
Study: 19380940

Group type: EXPERIMENTAL
Intervention: Telehealth network with an asynchronous clinical decision support system for health care providers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17672830

Group type: EXPERIMENTAL
Intervention: Super‐Bond C&B resin cement with 0.5 mm thick porcelain laminates bonded to enamel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scotchbond + Opal resin cement with 0.5 mm thick porcelain laminates bonded to enamel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with 0.5 mm thick porcelain laminates without resin cement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with 0.5 mm thick porcelain laminates bonded to dentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5 mm thick porcelain laminates bonded to enamel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.0 mm thick porcelain laminates bonded to dentin
Number of subjects: 40
Study: 17682320

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prostaglandin E1 (PG E1) at 0.05 microg/kg/min
Number of subjects: 60
Study: 10769331

Group type: EXPERIMENTAL
Intervention: Bran treatment (gradually increasing daily doses of a bran mixture)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 12
Study: 9152656

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg o.d.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ibopamine 100 mg t.d.s.
Number of subjects: 14
Study: 8478672

Group type: EXPERIMENTAL
Intervention: At-risk group
Number of subjects: 227

Group type: COMPARATOR
Intervention: Low-risk group
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 227
Study: 3739583

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous methohexitone
Number of subjects: 50
Study: 30802723

Group type: EXPERIMENTAL
Intervention: Fuji apple intake (2 apples, 360 g per day for 1 week)
Number of subjects: 16
Study: 27798749

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 every 28 days
Number of subjects: 210

Group type: COMPARATOR
Intervention: Capecitabine 1250 mg/m2 twice daily for 14 days every 21 days
Number of subjects: 210
Study: 27102874

Group type: EXPERIMENTAL
Intervention: hsTnT measurement preoperatively and at 6, 12, and 24 hours postoperatively, then every 24 hours for a maximum of 5 days
Number of subjects: 85
Study: 25138661

Group type: EXPERIMENTAL
Intervention: 30 g dose of the whole-grain fibre composite ingredient
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 g dose of the whole-grain fibre composite ingredient
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both doses of the whole-grain fibre composite ingredient
Number of subjects: 90

Group type: COMPARATOR
Intervention: Maltodextrin control
Number of subjects: 90
Study: 22771160

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (oral care with a toothbrush and antiseptic gel twice a day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (oral care with a toothbrush and non-antiseptic gel twice a day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 96
Study: 18982377

Group type: EXPERIMENTAL
Intervention: Chemically interesterified (CIE) stearic acid-rich fat spread
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enzymatically interesterified (EIE) stearic acid-rich fat spread
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-interesterified (NIE) stearic acid-rich fat spread
Number of subjects: 21

Group type: COMPARATOR
Intervention: No fat
Number of subjects: 21
Study: 17599102

Group type: EXPERIMENTAL
Intervention: Rocephin (Ceftriaxone) 1g intravenously at induction and 1g 12 hours later (Group 1)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Zinacef (Cefuroxime) 1.5 g intravenously at induction and 750 mg six hourly for 12 hours (Group 2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ciprotab (ciprofloxacine) 400mg intravenously at induction and 200mg six hourly for 12 hours (Group 3)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness comparison of the three antibiotics
Number of subjects: 89
Study: 15603456

Group type: EXPERIMENTAL
Intervention: Prelingually deafened students
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hearing control group
Number of subjects: 18
Study: 11752994

Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-video group
Number of subjects: 22
Study: 10220207

Group type: EXPERIMENTAL
Intervention: Insulin lispro injected at 0 min before a standard lunch with a mid-afternoon snack
Number of subjects: 10

Group type: COMPARATOR
Intervention: Humulin S (HS) injected at ‐30 min before lunch with a mid-afternoon snack
Number of subjects: 10
Study: 7882475

Group type: EXPERIMENTAL
Intervention: Angiopeptin (3 mg per 24 hours before PTCA followed by 6 mg per 24 hours after PTCA)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Angiopeptin
Number of subjects: 553
Study: 2122016

Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine (50 mumol/kg/day for 7 days, then 100 mumol/kg/day for 7 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine
Number of subjects: 43
Study: 363722

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119